CYP2E1 and lung carcinoma: In recent years, the strategy for cancer treatment has turned to the tumor microenvironment.[38] In the current study, we found that CYP2E1 could be a novel inflammatory target for the treatment of lung cancer, and our novel CYP2E1 inhibitor, Q11, is effective against lung cancer via regulation of inflammatory microenvironment.